431 related articles for article (PubMed ID: 32929230)
1. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus.
Deacon CF
Nat Rev Endocrinol; 2020 Nov; 16(11):642-653. PubMed ID: 32929230
[TBL] [Abstract][Full Text] [Related]
2. Role of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome.
Panda SP
Endocr Metab Immune Disord Drug Targets; 2023; 23(2):179-187. PubMed ID: 35642117
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis.
Cho YK; Kang YM; Lee SE; Lee J; Park JY; Lee WJ; Kim YJ; Jung CH
Diabetes Metab; 2018 Nov; 44(5):393-401. PubMed ID: 29449146
[TBL] [Abstract][Full Text] [Related]
4. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of combination therapy with an α-glucosidase inhibitor and a dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes mellitus: A systematic review with meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
J Diabetes Investig; 2018 Jul; 9(4):893-902. PubMed ID: 28950431
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2016; 9(2):229-40. PubMed ID: 26589238
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
[TBL] [Abstract][Full Text] [Related]
8. Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Campos C; Unger J
Postgrad Med; 2021 Nov; 133(8):843-853. PubMed ID: 34416133
[TBL] [Abstract][Full Text] [Related]
9. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
10. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
[TBL] [Abstract][Full Text] [Related]
12. Effects of dipeptidyl peptidase 4 inhibition on the endothelial control of the vascular tone.
Ribeiro-Silva JC; Marques VB; Dos Santos L
Am J Physiol Cell Physiol; 2023 Oct; 325(4):C972-C980. PubMed ID: 37642237
[TBL] [Abstract][Full Text] [Related]
13. Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment.
Yin R; Xu Y; Wang X; Yang L; Zhao D
Molecules; 2022 May; 27(10):. PubMed ID: 35630534
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
Hou WH; Chang KC; Li CY; Ou HT
Pain; 2016 Sep; 157(9):1954-1959. PubMed ID: 27127847
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular protection by DPP-4 inhibitors in preclinical studies: an updated review of molecular mechanisms.
Zakaria EM; Tawfeek WM; Hassanin MH; Hassaballah MY
Naunyn Schmiedebergs Arch Pharmacol; 2022 Nov; 395(11):1357-1372. PubMed ID: 35945358
[TBL] [Abstract][Full Text] [Related]
16. In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control.
Watanabe T; Temma Y; Okada J; Yamada E; Saito T; Osaki A; Shimda Y; Matsumoto S; Horiguchi K; Ishida E; Kondo Y; Okada K; Takamizawa T; Nakajima Y; Ozawa A; Okada S; Horigome M; Yamada M
Endocr J; 2021 May; 68(5):599-603. PubMed ID: 33408313
[TBL] [Abstract][Full Text] [Related]
17. Patterns and trends of utilization of incretin-based medicines between 2008 and 2014 in three Italian geographic areas.
Roberto G; Barone-Adesi F; Giorgianni F; Pizzimenti V; Ferrajolo C; Tari M; Bartolini C; Da Cas R; Maggini M; Spila-Alegiani S; Francesconi P; Trifirò G; Poluzzi E; Baccetti F; Gini R
BMC Endocr Disord; 2019 Feb; 19(1):18. PubMed ID: 30732592
[TBL] [Abstract][Full Text] [Related]
18. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
Dombrowski S; Kostev K; Jacob L
Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
[TBL] [Abstract][Full Text] [Related]
19. Clinical use of GLP-1 agonists and DPP4 inhibitors.
Tuch BE
Pancreatology; 2016; 16(1):8-9. PubMed ID: 26138513
[TBL] [Abstract][Full Text] [Related]
20. Early treatment with dipeptidyl-peptidase 4 inhibitors reduces glycaemic variability and delays insulin initiation in type 2 diabetes: A propensity score-matched cohort study.
Cheung JTK; Yang A; Wu H; Lau ESH; Kong APS; Ma RCW; Luk AOY; Chan JCN; Chow E
Diabetes Metab Res Rev; 2024 Jan; 40(1):e3711. PubMed ID: 37634071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]